1. MiR‐200c‐3p as a novel genetic marker and therapeutic tool for alopecia areata
   Ahmed Ibrahim AbdElneam et al, 2024, Skin Research and Technology CrossRef
2. Drug Repurposing Patent Applications April–June 2021
   Hermann Mucke, 2021, ASSAY and Drug Development Technologies CrossRef
3. Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors
   Yanmei Peng et al, 2018, BioScience Trends CrossRef
4. Dermatological adverse events associated with use of oral mechanistic target of rapamycin inhibitors in a cohort of individuals with tuberous sclerosis complex
   D.J. Pithadia et al, 2020, British Journal of Dermatology CrossRef
5. Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
   C. Grávalos et al, 2019, Clinical and Translational Oncology CrossRef
6. Adverse Hair Reactions to New Targeted Therapies for Cancer
   J.F. Mir-Bonafé et al, 2019, Actas Dermo-Sifiliográficas (English Edition) CrossRef
7. 220 Patient with T1N3M1 (liver) non-squamous NSCLC diagnosed July 2008. Subsequently confirmed EXON 18 EGFR mutation (2016) - Durable Survival, Late Effects: Learning from our patient's experiences over a 16 year period (2008 to the present)
   Paula Mulvenna et al, 2024, Lung Cancer CrossRef
8. Reacciones capilares de las nuevas terapias diana dirigidas contra el cáncer
   J.F. Mir-Bonafé et al, 2019, Actas Dermo-Sifiliográficas CrossRef